-
- Find A Provider
- Services
- Addiction Recovery
- Audiology
- Behavioral Health
- Cardiac Rehabilitation
- Cardiology
- Chiropractic Care
- Colon Cancer Screening
- Dermatology Services
- Diabetes Education
- Ear, Nose, and Throat
- ER & Urgent Care
- Family Medicine
- Home Care
- Hospice
- Infusion Therapy
- Kidney Health/Nephrology
- Laboratory
- Long Term Care Facility
- Men's Health
- Neurology
- Nutrition Services
- Orthopedics
- Pain Management
- Podiatry
- Radiology/Diagnostic Imaging
- Rehabilitation Services
- Respiratory Care
- Senior Care Unit
- Sleep Medicine
- Surgery
- Transitional Care
- Urology
- Weight Loss
- Women's Health
- Patients & Visitors
- Facilities & Pharmacy
- About Us
-
New oral meds for COVID-19 and submitting home test results
January 25, 2022
The FDA recently approved two new oral medications under an Emergency Use Authorization (EUA) for treatment of confirmed COVID-19 cases for certain eligible patients.
The two new pill options, Paxlovid and Molnupiravir, are for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 88 pounds). Patients must have confirmed positive results of COVID testing, and are at high risk for progression to severe COVID-19, including hospitalization or death.
Both medications are available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.
Paxlovid and Molnupiravir are not authorized for the pre-exposure or post-exposure prevention of COVID-19, or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. Neither is substitute for vaccination in individuals for whom COVID-19 vaccination and a booster dose are recommended.
The issuance of a EUA is different than an FDA approval. In determining whether to issue a EUA, the FDA evaluates the totality of scientific evidence available and carefully balances any known or potential risks with any known or potential benefits of the product. Based on the FDA’s review of the totality of the scientific evidence available, the agency has determined that it is reasonable to believe that Paxlovid and Molnupiravir may be effective for the treatment of mild-to-moderate COVID-19 in authorized patients.
Mille Lacs Health System has both oral medications available to certain patients that qualify. MLHS can accept pictures of home tests with your name, date, and time of test all included in the picture for treatment assessment.
If you have recently tested positive for COVID-19 and would like to inquire about the new oral treatment options start by calling MLHS at 320-532-3154.